American Century Companies Inc. lowered its holdings in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 5.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 406,929 shares of the specialty pharmaceutical company’s stock after selling 25,138 shares during the quarter. American Century Companies Inc. owned 0.79% of SciClone Pharmaceuticals worth $4,476,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. State of Alaska Department of Revenue increased its stake in SciClone Pharmaceuticals by 78.9% in the second quarter. State of Alaska Department of Revenue now owns 10,213 shares of the specialty pharmaceutical company’s stock valued at $112,000 after acquiring an additional 4,503 shares during the period. LS Investment Advisors LLC increased its stake in SciClone Pharmaceuticals by 425.2% in the first quarter. LS Investment Advisors LLC now owns 10,320 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 8,355 shares during the period. BNP Paribas Arbitrage SA increased its stake in SciClone Pharmaceuticals by 14.4% in the first quarter. BNP Paribas Arbitrage SA now owns 10,482 shares of the specialty pharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,320 shares during the period. Municipal Employees Retirement System of Michigan increased its stake in SciClone Pharmaceuticals by 2.7% in the first quarter. Municipal Employees Retirement System of Michigan now owns 11,660 shares of the specialty pharmaceutical company’s stock valued at $114,000 after acquiring an additional 310 shares during the period. Finally, Mason Street Advisors LLC increased its stake in SciClone Pharmaceuticals by 7.9% in the first quarter. Mason Street Advisors LLC now owns 12,037 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 881 shares during the period. 72.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of SciClone Pharmaceuticals, Inc. (SCLN) opened at 11.00 on Monday. SciClone Pharmaceuticals, Inc. has a 1-year low of $8.55 and a 1-year high of $11.43. The company has a 50-day moving average of $11.03 and a 200-day moving average of $10.29. The company has a market cap of $574.10 million, a PE ratio of 13.56 and a beta of 1.76.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02. SciClone Pharmaceuticals had a net margin of 25.18% and a return on equity of 21.10%. The business had revenue of $44.52 million during the quarter. Equities analysts forecast that SciClone Pharmaceuticals, Inc. will post $0.94 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “American Century Companies Inc. Has $4.48 Million Position in SciClone Pharmaceuticals, Inc. (SCLN)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/american-century-companies-inc-has-4-48-million-position-in-sciclone-pharmaceuticals-inc-scln/1553840.html.

In other news, VP Lan Xie sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $11.00, for a total value of $110,000.00. Following the completion of the transaction, the vice president now directly owns 10,000 shares in the company, valued at approximately $110,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Friedhelm Blobel sold 35,044 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $11.00, for a total transaction of $385,484.00. Following the completion of the transaction, the chief executive officer now owns 149,863 shares of the company’s stock, valued at $1,648,493. The disclosure for this sale can be found here. Insiders sold a total of 145,044 shares of company stock valued at $1,589,184 in the last quarter. Corporate insiders own 5.16% of the company’s stock.

Separately, Maxim Group reissued a “hold” rating on shares of SciClone Pharmaceuticals in a research note on Thursday, June 8th.

SciClone Pharmaceuticals Company Profile

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Want to see what other hedge funds are holding SCLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN).

Institutional Ownership by Quarter for SciClone Pharmaceuticals (NASDAQ:SCLN)

Receive News & Ratings for SciClone Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.